TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04349241
Drug: Standard of care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
Study: NCT03490149
Drug: Medication - Treatment as usual
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only sample - Treatment as usual
Study: NCT00283816
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules, two capsules BID
Study: NCT01571895
Drug: DF2156A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
Study: NCT03735316
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
Study: NCT00302458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered during the first part of the day, and again during the second part of the day.
Study: NCT01609335
Drug: F-18 FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time intravenous administration of 17 millicurie (mCi) +/- 10%
Study: NCT00509743
Drug: Intravenous diclofenac sodium (DIC075V)
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High dose Diclofenac
Study: NCT00509743
Drug: Intravenous diclofenac sodium (DIC075V)
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low Dose Diclofenac
Study: NCT03009643
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
Study: NCT04701164
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion
Study: NCT04701164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusion
Study: NCT02953665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
Study: NCT02106247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02437604
Drug: Treatment A: Fp MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 200 mcg, 1 inhalation
Study: NCT02437604
Drug: Treatment B: FS MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI 200/12.5 mcg, 1 inhalation
Study: NCT02437604
Drug: Treatment C Flovent
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOVENT DISKUS 250 mcg, 2 inhalations
Study: NCT02437604
Drug: Treatment D: Advair
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAIR DISKUS 500/50 mcg, 1 inhalation
Study: NCT01295736
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills TID per os during 90 days
Study: NCT00064766
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03187834
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children in this arm will receive Azithromycin once a day.
Study: NCT03187834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in this arm will receive Placebo once a day.
Study: NCT00841048
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending multiple doses(start dose 75mg od), oral suspension
Study: NCT00841048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02921386
Drug: Oral Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Study: NCT03333317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral administration of matching placebo.
Study: NCT03279523
Drug: F 18 T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT02075047
Drug: placebo oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
Study: NCT03498820
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous short-acting opioid routinely administered during general anesthesia
Study: NCT02821377
Drug: Hypertonic saline solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
Study: NCT03405935
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Study: NCT03397134
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a single dose once daily
Study: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after anaesthesia induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
Study: NCT02757443
Drug: 5% Glucose after anaesthesia induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Study: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate added to cardioplegia
Normalized name: Phosphocreatine
DrugBank: Phosphocreatine (DB13191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
Study: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after heart recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
Study: NCT02757443
Drug: 5% Glucose after heart recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Study: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after ICU admission
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
Study: NCT02757443
Drug: 5% Glucose after ICU admission
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
Study: NCT03287674
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study: NCT03383783
Drug: 0 ppm F (placebo, negative control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study: NCT03383783
Drug: 250 ppm F as NaF (dose-response control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study: NCT03383783
Drug: 500 ppm F as NaF (dose-response control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study: NCT03383783
Drug: 1100 ppm F as NaF (positive control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Study: NCT01703117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-22 subjects between the ages of 60-85 will receive placebo
Study: NCT01342965
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine were locally sourced with commercial products.
Study: NCT03691350
Drug: Cigarette
Normalized name: CIGARETTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoke usual brand
Study: NCT02978703
Drug: COPD Pharmacologic Substance
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
Study: NCT01646619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
Study: NCT02046070
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide tablets
Study: NCT00315107
Drug: Alesse
Normalized name: Alesse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02516826
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02516826
Drug: Combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/Olmesartan(Combination)
Study: NCT02516826
Drug: Placebo of Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02516826
Drug: Placebo of Rosuvastatin/Olmesartan(Combination)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03521713
Drug: EPORON
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS
Study: NCT03521713
Drug: EPREX
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS
Study: NCT01873053
Drug: WIN-34B
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
Study: NCT01873053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00343863
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00343863
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04130399
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
Study: NCT00052312
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03634371
Drug: Drug Levothyroxine 150 mcg
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT03634371
Drug: Drug Eutirox 150 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT00404170
Drug: B-CIT and SPECT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional ongoing B-CIT SPECT imaging scans at follow-up visits
Study: NCT01549795
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine - administered till liver transplantation
Study: NCT03283397
Drug: EK-12
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
Study: NCT00086502
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
Study: NCT02183129
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02183129
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01945775
Drug: Physician's-Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine, Eribulin, Gemcitabine or Vinorelbine
Study: NCT00650520
Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT04139681
Drug: A. Vogels Sore Throat lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 times 1 A. Vogels sore throat lozenges daily for 4 days
Study: NCT00110487
Drug: ERB-041
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251132
Drug: TPV low 1
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251132
Drug: TPV low 2
Normalized name: Dianeal Low Calcium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251132
Drug: TPV medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251132
Drug: Radiolabelled erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04008511
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 bid po for 14 days.
Study: NCT00803972
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human hyaluronidase PH20
Study: NCT01817790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle for Fluticasone propionate aqueous nasal spray
Study: NCT02418988
Drug: TACE plus rAd-p53 artery injection
Normalized name: SUS SCROFA ARTERY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
Study: NCT02097342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet placebo per oral, once daily will be given to 10 patients for 6 months
Study: NCT00003847
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00652899
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Study: NCT03254277
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117-LS
Study: NCT03254277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04214886
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
Study: NCT00844805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00844805
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00494559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug with the same appearance as actos
Study: NCT00034879
Drug: ZD1839 (Gefitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00857948
Drug: Placebo, vehicle control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application followed by thorough rinsing of the hair and scalp with water.
Study: NCT00605553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules~Placebo for 7 days
Study: NCT01889134
Drug: Sedron (alendronate)
Normalized name: Simaba cedron whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00023751
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00023751
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01400243
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT03726853
Drug: CKD-497 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of CKD-497
Study: NCT03726853
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT03726853
Drug: Comparator placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator placebo
Study: NCT01175200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator similar to lansoprazole
Study: NCT04346030
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study: NCT02193087
Drug: TDV Liquid Formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDV Liquid Formulation 2 for subcutaneous injection
Study: NCT02193087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDV liquid formulation placebo-matching solution for subcutaneous injection
Study: NCT02737995
Drug: Ferric carboxymaltose infusion
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
Study: NCT02715726
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02715726
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01707992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
Study: NCT00600769
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Study: NCT02226549
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study: NCT02654002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT03349866
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 bid d1-14
Study: NCT04196946
Drug: 25 mcg fentanyl
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
Study: NCT02008357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00627536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to avotermin dosage strength
Study: NCT00755534
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
Study: NCT03242018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
Study: NCT00088790
Drug: AZD5438
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03362697
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
Study: NCT00806923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv on day 1 of each 3 week cycle until disease progression
Study: NCT00131456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03527628
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
Study: NCT03823846
Drug: Routine Dynastat or Flurbiprofen Axetil jinjection
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.